
Barecetamab
CAS No. 2275727-74-5
Barecetamab( —— )
Catalog No. M36772 CAS No. 2275727-74-5
Barecetamab (ISU-104) is a humanized monoclonal antibody against tyrosine protein kinase ErbB3 with anticancer activity for use in investigational stage malignant solid tumors.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 499 | Get Quote |
![]() ![]() |
5MG | 1007 | Get Quote |
![]() ![]() |
10MG | 1359 | Get Quote |
![]() ![]() |
25MG | 1950 | Get Quote |
![]() ![]() |
50MG | 2631 | Get Quote |
![]() ![]() |
100MG | 3474 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameBarecetamab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBarecetamab (ISU-104) is a humanized monoclonal antibody against tyrosine protein kinase ErbB3 with anticancer activity for use in investigational stage malignant solid tumors.
-
DescriptionBarecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2275727-74-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kim SB, et, al. 887P Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). VOLUME 32, SUPPLEMENT 5, S797, SEPTEMBER 01, 2021.
molnova catalog



related products
-
WZ4002
WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.
-
Methyl 2,5-dihydroxy...
Methyl 2,5-dihydroxycinnamate is an EGF receptor-associated tyrosine kinases inhibitor.
-
Tyrphostin A1
Tyrphostin A1 is an inhibitor of EGFR tyrosine kinase .